CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(04): 469-480
DOI: 10.1055/a-1397-7170
GebFra Science
Review/Übersicht

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Article in several languages: English | deutsch
Michael P. Lux
1  Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Germany
,
Andreas Schneeweiss
2  National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
,
Andreas D. Hartkopf
3  Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
,
Volkmar Müller
4  Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Wolfgang Janni
5  Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Erik Belleville
6  ClinSol GmbH & Co. KG, Würzburg, Germany
,
Elmar Stickeler
7  Department of Gynecology and Obstetrics, RWTH University Hospital Aachen, Aachen, Germany
,
Marc Thill
8  Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt, Germany
,
Peter A. Fasching
9  Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Hans-Christian Kolberg
10  Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
,
Michael Untch
11  Department of Gynecology and Obstetrics, Helios Clinics Berlin Buch, Berlin, Germany
,
Nadia Harbeck
12  Breast Center, Department of Gynecology and Obstetrics, CCC Munich, LMU University Hospital, Munich, Germany
,
Achim Wöckel
13  Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
,
Christoph Thomssen
14  Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
,
Carla E. Schulmeyer
9  Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Manfred Welslau
15  Onkologie Aschaffenburg, Aschaffenburg, Germany
,
Friedrich Overkamp
16  OncoConsult Overkamp, Berlin, Germany
,
Florian Schütz
17  Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany
,
Diana Lüftner
18  Charité University Hospital, Department of Hematology, Oncology and Tumour Immunology, University Medicine Berlin, Berlin, Germany
,
Nina Ditsch
19  Frauenklinik, Universitätsklinikum Augsburg, Augsburg, Germany
› Author Affiliations

Abstract

In recent years, significant progress has been made in new therapeutic approaches to breast cancer, particularly in patients with HER2-positive and HER2-negative/hormone receptor-positive (HR+) breast cancer. In the case of HER2-positive tumours, these approaches have included, in particular, treatment with pertuzumab, T-DM1, neratinib and, soon, also tucatinib and trastuzumab deruxtecan (neither of which has yet been authorised in Europe). In patients with HER2−/HR+ breast cancer, CDK4/6 inhibitors and the PIK3CA inhibitor alpelisib are of particular importance. Further novel therapies, such as Akt kinase inhibitors and oral SERDs (selective estrogen receptor down regulators), are already being investigated in ongoing clinical trials. These therapeutic agents are not only being introduced into curative, (neo-)adjuvant therapeutic settings for HER2-positive tumours; a first favourable study on abemaciclib as an adjuvant therapy has now also been published. In patients with triple-negative breast cancer, after many years of negative study results with the Trop-2 antibody drug conjugate (ADC) sacituzumab govitecan, a randomised study has been published that may represent a significant therapeutic advance. This review describes the latest developments in breast cancer subsequent to the ESMO Congress 2020.



Publication History

Received: 17 December 2020

Accepted after revision: 20 February 2021

Publication Date:
14 April 2021 (online)

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany